Inclusion Criteria:

- Age ≥18 years

- Patients with histologically or cytologically documented diagnosis of locally
advanced NSCLC stage IIB to IIIB without pleural effusion

- Performance status 0-1 on the ECOG scale

- Weight loss ≤10% during the last 6 months

- Adequate lung function measured as FEV1 ≥1.0

- Neutrophile count ≥1.5 x 109/L and platelet count ≥100 x 109/L

- Serum bilirubin ≤1.5 upper limit of normal (ULN)

- ALAT ≤2 x ULN

- Able to comply with study and follow-up procedures

- Patients with reproductive potential must use effective contraception

- Written (signed) informed consent to participate in the study

Exclusion Criteria:

- Any unstable systemic disease (including active infection, unstable angina,
congestive heart failure, severe hepatic, renal, or metabolic disease)

- Any other active malignancies within 5 years (except for adequately treated carcinoma
in situ of the cervix or basal or squamous cell skin cancer)

- Prior chemotherapy for lung cancer, including neo- and adjuvant chemotherapy

- Inability to take oral medication, or requirement of intravenous alimentation

- Active peptic ulcer disease

- Nursing mothers